Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

Michel Seymour(University of Leeds), Ruth E. Langley(MRC Clinical Trials Unit at UCL), Gary Middleton(University Hospitals Birmingham NHS Foundation Trust), Lindsay C Thompson(MRC Clinical Trials Unit at UCL), Harpreet Wasan(Hammersmith Hospital), Tim Maughan(University of Liverpool), A. Brewster(Velindre NHS Trust), M. S. O'Mahony(Cardiff University), Stephen F Shepherd(Cheltenham General Hospital), Mahesh Parmar(University College London)
The Lancet
May 1, 2011
10.1016/s0140-6736(11)60399-1
Cited by 420

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k